CELSION CORPORATION (NASDAQ:CLSN) Files An 8-K Regulation FD Disclosure

0

CELSION CORPORATION (NASDAQ:CLSN) Files An 8-K Regulation FD Disclosure
Item 7.01

Regulation FD Disclosure.

On October 27, 2017, the Company issued a press release announcing the pricing and terms of the Offering. A copy of the press release is attached hereto as Exhibits 99.1, and is incorporated herein by reference.

to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934.

Item 9.01

Financial statements and Exhibits.

(d)Exhibits.

ExhibitNo.

Description

99.1

Press Release issued by Celsion Corporation dated October 27, 2017


Celsion CORP Exhibit
EX-99.1 2 ex_97803.htm EXHIBIT 99.1 ex_97803.htm Exhibit 99.1            Celsion Corporation Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock       LAWRENCEVILLE,…
To view the full exhibit click here

About CELSION CORPORATION (NASDAQ:CLSN)

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).